News
-
-
-
-
-
PRESS RELEASE
Valbiotis invited to present clinical results at the American Diabetes Association’s 84th Scientific Sessions
Valbiotis invited to present clinical results from TOTUM•63 Phase II/III REVERSE-IT study in prediabetes and type 2 diabetes at the American Diabetes Association’s 84th Scientific Sessions -
-
-
-
-
PRESS RELEASE
Valbiotis reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science
Valbiotis terminates licensing and supply agreement with Nestlé Health Science, securing full ownership of TOTUM•63 for diabetes treatment. Strategic control and future partnerships planned